Celldex Therapeutics (CLDX) Return on Sales (2016 - 2025)
Historic Return on Sales for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to 86.36%.
- Celldex Therapeutics' Return on Sales fell 731600.0% to 86.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.36%, marking a year-over-year decrease of 709100.0%. This contributed to the annual value of 22.49% for FY2024, which is 19400.0% down from last year.
- Per Celldex Therapeutics' latest filing, its Return on Sales stood at 86.36% for Q3 2025, which was down 731600.0% from 77.53% recorded in Q2 2025.
- In the past 5 years, Celldex Therapeutics' Return on Sales ranged from a high of 3.84% in Q2 2021 and a low of 220.88% during Q2 2022
- In the last 5 years, Celldex Therapeutics' Return on Sales had a median value of 60.32% in 2021 and averaged 71.4%.
- In the last 5 years, Celldex Therapeutics' Return on Sales plummeted by -2170400bps in 2022 and then soared by 1329000bps in 2025.
- Quarter analysis of 5 years shows Celldex Therapeutics' Return on Sales stood at 60.32% in 2021, then soared by 73bps to 16.42% in 2022, then skyrocketed by 36bps to 10.48% in 2023, then crashed by -282bps to 40.08% in 2024, then tumbled by -115bps to 86.36% in 2025.
- Its last three reported values are 86.36% in Q3 2025, 77.53% for Q2 2025, and 77.4% during Q1 2025.